On Invalid Date, Incyte (NASDAQ: INCY) reported Q3 2023 earnings per share (EPS) of $0.76, up 49.02% year over year. Total Incyte earnings for the quarter were $171.27 million. In the same quarter last year, Incyte's earnings per share (EPS) was $0.51.
As of Q4 2023, Incyte's earnings has grown -52.27% year over year. This is 68.6 percentage points lower than the US Biotechnology industry earnings growth rate of 16.33%. Incyte's earnings in the past year totalled $424.98 million.
On Invalid Date, Incyte (NASDAQ: INCY) reported Q3 2023 revenue of $919.03 million up 11.63% year over year. In the same quarter last year, Incyte's revenue was $823.30 million.
What was INCY's revenue growth in the past year?
As of Q4 2023, Incyte's revenue has grown 8.35% year over year. This is 103.65 percentage points lower than the US Biotechnology industry revenue growth rate of 112.01%. Incyte's revenue in the past year totalled $3.61 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.